TSX:EPRX (Canada)  
Eupraxia Pharmaceuticals Inc logo

Eupraxia Pharmaceuticals Inc

C$ 2.27 (+8.61%) Sep 29
P/E:
At Loss
P/B:
1.97
Market Cap:
C$ 48.56M ($ 35.53M)
Enterprise V:
C$ 23.13M ($ 16.92M)
Volume:
1.79K
Avg Vol (2M):
33.81K
Also Trade In:
Volume:
1.79K
Market Cap C$:
48.56M
Market Cap $:
35.53M
PE Ratio:
At Loss
Avg Vol (2-Month):
33.81K
Enterprise Value C$:
23.13M
Enterprise Value $:
16.92M
PB Ratio:
1.97
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations.
Name Current Vs Industry Vs History
Cash-To-Debt 3.54
Equity-to-Asset 0.67
Debt-to-Equity 0.41
Debt-to-EBITDA -0.58
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -16.1
3-Year EPS without NRI Growth Rate -22.2
3-Year FCF Growth Rate -22.7

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 78.99
9-Day RSI 75.66
14-Day RSI 74.59
6-1 Month Momentum % -31.41
12-1 Month Momentum % -54.83

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 10.13
Quick Ratio 10.13
Cash Ratio 9.87

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -3.4
Name Current Vs Industry Vs History
ROE % -80.97
ROA % -55.13
ROIC % -2592.56
ROC (Joel Greenblatt) % -3254.44
ROCE % -56.1

Financials

TSX:EPRX's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil C$) 0
EPS (TTM) (C$) -1.15
Beta 0
Volatility % 70.6
14-Day RSI 74.59
14-Day ATR (C$) 0.104248
20-Day SMA (C$) 1.8715
12-1 Month Momentum % -54.83
52-Week Range (C$) 0.8 - 3
Shares Outstanding (Mil) 21.39

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Eupraxia Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Eupraxia Pharmaceuticals Inc Analysis

Share your research